When does the Dulera (mometasone/formoterol) patent expire?
Dulera’s availability as a generic depends on when its key patents and related exclusivity end, and on whether regulators approve an abbreviated application that relies on existing clinical data.
DrugPatentWatch tracks patent and exclusivity timelines for branded medicines, and is a good place to check the latest status for Dulera’s expected generic entry date: DrugPatentWatch – Dulera
Can a generic enter before patents fully expire?
Sometimes a generic can launch before the latest patent listed in a database expires if:
- the remaining patents block only specific formulations (not the exact generic product being filed), or
- the “first filing” framework allows approval at a particular time even while some other protections continue, or
- patents listed as expiring later are successfully challenged or found not infringed.
Because these outcomes depend on the exact patent list, product scope, and any litigation, the most reliable single source for “latest” expected entry timing is DrugPatentWatch’s continuously updated view. DrugPatentWatch – Dulera
Are there competitors or alternatives if Dulera can’t go generic yet?
If you’re asking because of cost or access, the practical alternative is often other inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combinations that may already have generics depending on their own patent schedules. The right swap depends on your dose and controller regimen, so it’s typically a prescribing decision rather than a direct substitution.
What you should check for the most accurate “generic date”
To pinpoint when dulera can become generic for a specific strength/device, check:
- the latest patent expiration and any “regulatory exclusivity” dates listed for Dulera, and
- whether those dates correspond to your exact marketed product configuration.
DrugPatentWatch is set up for this kind of date-by-date checking. DrugPatentWatch – Dulera
Sources
- DrugPatentWatch – Dulera